Presence of Minor Anti Phospholipid Antibodies in Blood Samples of Ischemic Stroke Patients and Healthy Controls
1 other identifier
observational
207
1 country
1
Brief Summary
The investigators expect to find higher levels of both classical and minor antiphospholipid (APL) antibodies among the stroke cases. Furthermore, the investigators expect to find not only classical APLA but also minor antibodies. The investigators believe that minor antibodies have a major role in the hypercoagulability state.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2011
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2011
CompletedFirst Submitted
Initial submission to the registry
December 5, 2011
CompletedFirst Posted
Study publicly available on registry
December 7, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2012
CompletedDecember 7, 2011
December 1, 2011
3 months
December 5, 2011
December 6, 2011
Conditions
Keywords
Study Arms (2)
treatment
Stroke patients
Controls
healthy controls
Eligibility Criteria
on a bank of 207 stroke patients serum samples, and also on 40 healthy controls. The samples were collected during the acute phase of the ischemic event.
You may qualify if:
- stroke diagnosis
- blood sampling within 36hrs from the event
- written agreement
You may not qualify if:
- a stroke, MI or major operation prior to the current stroke
- hypercoagulable state known in this patient
- a severe chronic disease known at the time of the stroke
- an infection on arrival (based on anamnesis, physical exam and lab tests)
- thrombolytic treatment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Meir Medical Centerlead
- Sheba Medical Centercollaborator
Study Sites (1)
Meir health center
Kfar Saba, Israel
Biospecimen
Serum samples of Stroke patients withdrawned within 36 hrs since stroke evoked. Healthy controls
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 5, 2011
First Posted
December 7, 2011
Study Start
December 1, 2011
Primary Completion
March 1, 2012
Study Completion
September 1, 2012
Last Updated
December 7, 2011
Record last verified: 2011-12